Etanercept therapy for toxic epidermal necrolysis - 16/07/14
Abstract |
Background |
Toxic epidermal necrolysis (TEN) is a severe and potentially lethal drug reaction for which no standard treatment is available.
Objective |
To describe a case series of patients with TEN treated with a single dose of etanercept.
Methods |
We observed 10 consecutive patients with TEN. For each patient, we recorded the presence of comorbidities and all the drugs recently started (ie, in the last month). In all cases, 50 mg of etanercept was administered in a single subcutaneous injection. The clinical severity of disease was computed using the SCORe of Toxic Epidermal Necrosis (SCORTEN) scale. Using the probabilities of death linked to each level of SCORTEN score, we calculated the expected probability of death in our patients. Healing was defined as complete reepithelialization, and a time to healing curve was then obtained using the Kaplan–Meier method.
Results |
All patients promptly responded to treatment, reaching complete reepithelialization without complications or side effects. The median time to healing was 8.5 days.
Limitations |
This is a small, uncontrolled case series.
Conclusion |
These preliminary results suggest the possibility that tumor necrosis factor–alfa may be an effective target for control of TEN, a dangerous skin condition for which no effective cure has yet been found.
Le texte complet de cet article est disponible en PDF.Key words : adverse drug reaction, etanercept, therapy, toxic epidermal necrolysis
Plan
Supported in part by the “Progetto Ricerca Corrente 2014” given by the Italian Ministry of Health to the Health Services Research Unit of the IDI-IRCCS, Rome, Italy (grant number Progetto Ricerca Corrente 2012: 5.3 [Strumenti e misure per la descrizione e la valutazione della gravità delle malattie dermatologiche]). |
|
Conflicts of interest: None declared. |
Vol 71 - N° 2
P. 278-283 - août 2014 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?